Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the FIT Biotech Oy ("Company") and Bracknor Investment ("Bracknor") the Company's board of directors have resolved on August 25, 2017 to approve Bracknor's request relating to the funding programme to convert EUR 25,000 worth of Convertible Capital Notes into the Company's K shares.

Due to the conversion of the Convertible Capital Notes, the Company issues 722,647 new K shares in the Company to Bracknor with the conversion price of EUR 0.034595 per share.

As a result of the issue of the new K shares in the Company, the total number of shares in the Company will increase to 70,106,539 shares, and the share capital of the Company will be increased by EUR 24,999.97. After the issue of the new K shares in the Company, the Company's shares will be divided in share series as follows: 70,036,075 K shares, 5,229 A shares and 65,235 D shares.

The increase of the share capital and new K shares in the Company will be registered in the Trade Register on or about August 29, 2017 and the new K shares will be admitted to trading on First North Finland on or about August 30, 2017.

FIT BIOTECH OY

Board of Directors

For further information: Chairman of the Board of Directors Rabbe Slätis E-mail: rabbe.slatis@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.